Comparison of the outcomes between early and late anti-tumor necrosis factor therapy in patients with enthesitis-related subcategory of juvenile idiopathic arthritis: a multi-center study in Southeast Asia

References

• Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–392.
   PubMed Web of Science ®Google Scholar
• Demirkaya E, Ozen S, and Bilginer Y, et al. The distribution of juvenile idiopathic arthritis in the eastern Mediterranean: results from the registry of the Turkish Paediatric Rheumatology Association. Clin Exp Rheumatol. 2011;29:111–116.
   PubMed Web of Science ®Google Scholar
• Stone M, Warren RW, Bruckel J, et al. Juvenile‐onset ankylosing spondylitis is associated with worse functional outcomes than adult‐onset ankylosing spondylitis. Arthritis Rheum. 2005;53:445–451.
   PubMed Web of Science ®Google Scholar
• Guo R, Cao L, Kong X, et al. Fever as an initial manifestation of enthesitis-related arthritis subtype of juvenile idiopathic arthritis: retrospective study. PLoS One. 2015;10:e0128979.
   PubMed Web of Science ®Google Scholar
• Arkachaisri T, Teh KL, and Book YX, et al. Enthesitis related arthritis in a longitudinal Southeast Asian registry: high prevalence of HLA-B27, different sacroiliitis risk factors and less common drug-free remission. J Clin Med. 2021;10:568.
   PubMed Web of Science ®Google Scholar
• Shih Y-J, Yang Y-H, Lin C-Y, et al. Enthesitis-related arthritis is the most common category of juvenile idiopathic arthritis in Taiwan and presents persistent active disease. Pediatr Rheumatol. 2019;17:1–8.
   PubMed Web of Science ®Google Scholar
• Goirand M, Breton S, Chevallier F, et al. Clinical features of children with enthesitis-related juvenile idiopathic arthritis/juvenile spondyloarthritis followed in a French tertiary care pediatric rheumatology centre. Pediatr Rheumatol. 2018;16:1–9.
   PubMed Web of Science ®Google Scholar
• Gmuca S, Xiao R, Brandon TG, et al. Multi-center inception cohort of enthesitis-related arthritis: variation in disease characteristics and treatment approaches. Arthr Res Ther. 2017; 19: 1–10.
   PubMed Web of Science ®Google Scholar
• Srivastava R, Agnihotry S, Aggarwal R, et al. HLA-B27 subtypes in enthesitis-related arthritis category of juvenile idiopathic arthritis and ankylosing spondylitis in northern India. Clin Exp Rheumatol. 2015;33:931–935.
   PubMed Web of Science ®Google Scholar
• Pagnini I, Savelli S, Matucci-Cerinic M, et al. Early predictors of juvenile sacroiliitis in enthesitis-related arthritis. J Rheumatol. 2010;37:2395–2401.
   PubMed Web of Science ®Google Scholar
• Antoun MB, Adamsbaum C, Semerano L, et al. Clinical predictors of magnetic resonance imaging-detected sacroiliitis in children with enthesitis related arthritis. Joint Bone Spine. 2017;84:699–702.
   PubMed Web of Science ®Google Scholar
• Schett G, Lories RJ, D’Agostino M-A, et al. Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol. 2017;13:731–741.
   PubMed Web of Science ®Google Scholar
• Sen ES, Ramanan A. Juvenile idiopathic arthritis-associated uveitis. Best Pract Res Clin Rheumatol. 2017;31:517–534.
   PubMed Web of Science ®Google Scholar
• Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. 2011;63:465–482.
   PubMed Web of Science ®Google Scholar
• Ringold S, Angeles-Han ST, and Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res. 2019;71:717–734.
   PubMed Web of Science ®Google Scholar
• Beukelman T, Lougee A, Matsouaka RA, et al. Patterns of etanercept use in juvenile idiopathic arthritis in the childhood arthritis and rheumatology research alliance registry. Pediatr Rheumatol Online J. 2021;19:131.
   PubMedGoogle Scholar
• Vilaiyuk S, Soponkanaporn S, Jaovisidha S, et al. A retrospective study on 158 Thai patients with juvenile idiopathic arthritis followed in a single center over a 15‐year period. Int J Rheum Dis. 2016;19:1342–1350.
   PubMedGoogle Scholar
• Tay SH, Yeo JG, Leong JY, et al. Juvenile spondyloarthritis: what more do we know about HLA-B27, enthesitis, and new bone formation? Front Med. 2021;8:666772.
   Web of Science ®Google Scholar
• Horneff G, Foeldvari I, and Minden K, et al. Efficacy and safety of etanercept in patients with the enthesitis‐related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double‐blind study. Arthr Rheumatol. 2015;67:2240–2249.
   PubMed Web of Science ®Google Scholar
• Burgos‐Vargas R, Tse SM, and Horneff G, et al. A randomized, double‐blind, placebo‐controlled multi-center study of Adalimumab in pediatric patients with enthesitis‐related arthritis. Arthritis Care Res. 2015;67:1503–1512.
   PubMed Web of Science ®Google Scholar
• Papsdorf V, and Horneff G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatol. 2011;50:214–221.
   PubMed Web of Science ®Google Scholar
• Horneff G, Burgos-Vargas R, Constantin T, et al. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis. 2014;73:1114–1122.
   PubMed Web of Science ®Google Scholar
• Constantin T, Foeldvari I, Vojinovic J, et al. Two-year efficacy and safety of etanercept in pediatric patients with extended oligoarthritis, enthesitis-related arthritis, or psoriatic arthritis. J Rheumatol. 2016;43:816–824.
   PubMed Web of Science ®Google Scholar
• Davies R, Gaynor D, and Hyrich KL, et al. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: a systematic review. Semin Arthritis Rheum. 2017;46:584–593.
   PubMed Web of Science ®Google Scholar
• Weiss PF, Colbert RA, Xiao R, et al. Development and retrospective validation of the juvenile spondyloarthritis disease activity index. Arthritis Care Res. 2014;66:1775–1782.
   PubMed Web of Science ®Google Scholar
• Consolaro A, Ruperto N, Bazso A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61:658–666.
   PubMed Web of Science ®Google Scholar
• Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202–1209.
   PubMed Web of Science ®Google Scholar
• Sontichai W, Vilaiyuk S. The correlation between the childhood health assessment questionnaire and disease activity in juvenile idiopathic arthritis. Musculoskeletal Care. 2018;16:339–344.
   PubMed Web of Science ®Google Scholar
• Wallace CA, Ruperto N, Giannini E, et al. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol. 2004;31:2290–2294.
   PubMed Web of Science ®Google Scholar
• Alexeeva EI, Namazova-Baranova LS, Bzarova TM, et al. Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children’s Health, Russia. Pediatr Rheumatol. 2017;15:1–11.
   PubMed Web of Science ®Google Scholar
• Donnithorne KJ, Cron RQ, and Beukelman T. Attainment of inactive disease status following initiation of TNF-α inhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active disease. J Rheumatol. 2011;38:2675–2681.
   PubMed Web of Science ®Google Scholar
• Prince FH, Twilt M, ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis. 2009;68:635–641.
   PubMed Web of Science ®Google Scholar
• Windschall D, Müller T, Becker I. Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis. Clin Rheumatol. 2015;34:61–69.
   PubMed Web of Science ®Google Scholar
• Otten MH, Prince FH, Twilt M, et al. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis—data from the Dutch arthritis and biologicals in children register, 1999–2010. J Rheumatol. 2011;38:2258–2263.
   PubMed Web of Science ®Google Scholar
• Berntson L, Damgård M, Andersson-Gäre B, et al. HLA-B27 predicts a more extended disease with increasing age at onset in boys with juvenile idiopathic arthritis. J Rheumatol. 2008;35:2055–2061.
   PubMed Web of Science ®Google Scholar
• Savolainen H, Lehtimäki M, Kautiainen H, et al. HLA B27: a prognostic factor in juvenile chronic arthritis. Clin Rheumatol. 1998;17:121–124.
   PubMed Web of Science ®Google Scholar
• Berntson L, Nordal E, Aalto K, et al. HLA-B27 predicts a more chronic disease course in an 8-year follow up cohort of patients with juvenile idiopathic arthritis. J Rheumatol. 2013;40:725–731.
   PubMedGoogle Scholar
• Vilaiyuk S, Lerkvaleekul B, and Thammanichanond D. Associations between HLA-B27 subtypes and outcomes in Thai children with enthesitis-related arthritis. Clin Rheumatol. 2021;41:203–212.
   PubMed Web of Science ®Google Scholar
• Kearsley-Fleet L, Davies R, Lunt M, et al. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with juvenile idiopathic arthritis: results from the British Society for paediatric and adolescent rheumatology etanercept cohort study. Rheumatol. 2016;55:840–847.
   PubMed Web of Science ®Google Scholar
• Wallace CA, Giannini EH, Spalding SJ, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012;64:2012–2021.
   PubMed Web of Science ®Google Scholar
• Tynjälä P, Vähäsalo P, Tarkiainen M, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE–JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis. 2011;70:1605–1612.
   PubMed Web of Science ®Google Scholar
• Pacharapakornpong T, Vallibhakara SA, Lerkvaleekul B, et al. Comparisons of the outcomes between early and late tocilizumab treatment in systemic juvenile idiopathic arthritis. Rheumatol Int. 2017;37:251–255.
   PubMed Web of Science ®Google Scholar
• Mistry RR, Patro P, Agarwal V, et al. Enthesitis-related arthritis: current perspectives. Open Access Rheumatol. 2019;11:19–31.
   PubMed Web of Science ®Google Scholar